FINACEA GEL
País: Canadà
Idioma: anglès
Font: Health Canada
Fitxa tècnica
(SPC)
18-09-2019
Alguns documents d’aquest producte actualment no estan disponibles, podeu enviar una sol·licitud al nostre servei d’atenció al client i us ho notificarem tan bon punt puguem obtenir-los.
Enviar sol.licitud.
Enviar sol.licitud.
ingredients actius:
AZELAIC ACID
Disponible des:
LEO PHARMA INC
Codi ATC:
D10AX03
Designació comuna internacional (DCI):
AZELAIC ACID
Dosis:
15%
formulario farmacéutico:
GEL
Composición:
AZELAIC ACID 15%
Vía de administración:
TOPICAL
Unidades en paquete:
15G/50G
tipo de receta:
Prescription
Área terapéutica:
MISC. SKIN AND MUCOUS MEMBRANE AGENTS
Resumen del producto:
Active ingredient group (AIG) number: 0126787002; AHFS:
Estat d'Autorització:
APPROVED
Data d'autorització:
2005-09-02
Fitxa tècnica
_FINACEA Product Monograph, version 1.0_
_Page 1 of 20 _
PRODUCT MONOGRAPH
PR FINACEA
®
Azelaic Acid Gel
15% w/w
Topical
Antirosacea Agent
LEO Pharma Inc.
Thornhill, Ontario
L3T 7W8
www.leo-pharma.ca
Submission Control No.: 229634
Date of Revision:
September 18, 2019
®Registered trademark of LEO Pharma A/S used under license by LEO
Pharma Inc., Thornhill, ON
_FINACEA Product Monograph, version 1.0_
_Page 2 of 20 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................3
ADVERSE REACTIONS
....................................................................................................5
DRUG INTERACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................7
OVERDOSAGE
..................................................................................................................7
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
............................................................................................9
SPECIAL HANDLING INSTRUCTIONS
.........................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................9
PART II: SCIENTIFIC INFORMATION
...............................................................................10
PHARMACEUTICAL INFORMATION
................................................
Llegiu el document complet
